Vinpocetine - instructions for use, dose, side effects, contraindications

Vinpocetine selectively inhibits potential-dependent Na + channels, causing a dose-dependent decrease in Ca2 + concentration in the endings of the striatum neurons. It is believed that a decrease in the current of Na + has a neuroprotective effect due to a decrease in excitotoxicity and a weakening of neuronal damage caused by cerebral ischemia or reperfusion.

Increases the concentration of 3,4-dihydroxyphenylacetic acid (dopamine metabolite) in the nerve endings of the striatum.

Inhibits type 1 phosphodiesterase (PDE-1), which increases the concentration of intracellular cyclic guanosine monophosphate (cGMP). This leads to a relaxation of the smooth muscles of the vessels of the brain.

Pharmacokinetics:

When ingested quickly and completely absorbed in the gastrointestinal tract (mainly in the proximal parts of the small intestine). The bioavailability when taken on an empty stomach is about 7%. Time to reach the maximum concentration (TCmax) in blood plasma is 1 hour, in tissues - 2-4 hours. When passing through the wall of the intestine is not exposed to metabolism. When introducing repeated doses, the kinetics is linear.

The connection with plasma proteins is 66%. Penetrates into breast milk (0.25% within 1 hour) and through the placental barrier. The clearance is 66.7 l / h and exceeds the hepatic clearance (50 l / h), which indicates extrahepatic metabolism.

The half-life (T1 / 2) is 3.54-6.12 hours. It is excreted by the kidneys and intestines in a ratio of 3: 2.

Indications:

Perceptive hearing loss, Meniere's disease, idiopathic tinnitus.

Chronic vascular diseases of the choroid and retina (including occlusion of the central artery or vein of the retina).

As a symptomatic agent in the complex therapy of various forms of cerebral circulatory insufficiency (ischemic stroke, the recovery period of hemorrhagic stroke, the consequences of a stroke, transient ischemic attack, vascular dementia, circulatory failure in the vertebrobasilar pool, cerebral atherosclerosis, posttraumatic and hypertensive encephalopathy).

Contraindications:

- hypersensitivity to the components of the drug;

- acute period of hemorrhagic stroke;

- severe forms of coronary heart disease;

- severe heart rhythm disturbances;

- pregnancy;

- lactation period;

- age to 18 years;

-lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Carefully:

Use with caution inward with arrhythmia, angina pectoris, labile arterial pressure (BP).

Pregnancy and lactation:

The drug is contraindicated for use during pregnancy.

Penetrates into breast milk, during the treatment should stop breastfeeding.

Dosing and Administration:

Inside, after eating. The initial dose is 15 mg / day (5 mg 3 times a day), the standard daily dose is 5-10 mg 3 times a day. The maximum daily dose is 30 mg. The course of treatment - 1 3 months. If you cancel the drug, gradually reduce the dose to 15 mg / day, for 2-3 days.

Side effects:

From the cardiovascular system: changes on the electrocardiogram (ECG) - segment depression ST, elongation Q-T interval; tachycardia, extrasystole (cause-and-effect relationship not established), lability of blood pressure (often decrease).

From the central nervous system: sleep disturbance (insomnia, increased drowsiness); dizziness, headache, general weakness (may be a manifestation of the underlying disease).

From the digestive system: dryness of the oral mucosa, nausea, heartburn.

Other: skin allergic reactions, increased sweating, skin hyperemia.

If these adverse reactions occur, stop taking the medication and consult a doctor.

Overdose:

Symptoms of overdose are unknown.In case of overdose, it is possible to assume the appearance or intensification of side effects (primarily cardiovascular) effects.

Treatment: cancellation of the drug, gastric lavage, reception of activated charcoal, symptomatic treatment.

Interaction:

Increases the risk of hemorrhagic complications against heparin therapy.

Strengthens the effect of antihypertensive drugs. When used simultaneously with antihypertensive drugs (methyldopa), blood pressure control is necessary.

Special instructions:In the case of the initial elongation of Q-T interval, and while the use of drugs that prolong the Q-T interval during treatment vinpocetine requires periodic monitoring of an electrocardiogram.

Effect on the ability to drive transp. cf. and fur:The drug should not be used during work for people whose profession is associated with the performance of potentially hazardous activities requiring special attention and quick reactions (driving and other vehicles, working with moving mechanisms, dispatcher and operator work, etc.).

Form release / dosage:Tablets 5 mg.

Packaging:

10 tablets per contour cell packaging made of polyvinylchloride film and aluminum foil foillacquered.

2 or 5 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:In the dark place at a temperature of no higher than 25 degrees С. Keep out of the reach of children.

Shelf life:2 years. Do not use after the expiry date stated on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N000173 / 01

Date of registration:16.09.2011

Expiration Date:Unlimited

The owner of the registration certificate:VALENTA PHARM, PAO VALENTA PHARM, PAO Russia

Manufacturer: & nbsp

VALENTA PHARMACEUTICS, JSC Russia

Information update date: & nbsp18.02.2017

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)